Rheumatology.Physio Podcast

Jack March

Content from Rheumatology.Physio projects rheumatologyphysio.substack.com

  1. What Does A Rheumatologist Do?

    FEB 26

    What Does A Rheumatologist Do?

    Welcome Back Rheumatology Fans! What on earth does a Rheumatologist do? What ingredients make up the secret sauce? Watch the video to find out and I have sorted a little summary below if you are strapped for time. Video Summary What actually happens after you refer someone to rheumatology with suspected psoriatic arthritis (PsA)? It’s a question many clinicians ask — particularly because PsA doesn’t come with a neat, definitive diagnostic test. This episode walks through what really goes on behind the clinic door. Psoriatic arthritis is a clinical diagnosis. While investigations can support it, they are often inconclusive. Around 90% of patients will have a negative rheumatoid factor. HLA-B27 is negative in roughly half of cases (higher in axial presentations), and inflammatory markers such as ESR and CRP are only elevated about 50% of the time. Imaging isn’t foolproof either — ultrasound and MRI may show inflammatory changes, but only if the right structures are scanned at the right time. So what are rheumatologists doing differently? Primarily, they are applying highly developed clinical reasoning. The initial consultation looks remarkably similar to a skilled MSK assessment: detailed history, joint examination, skin assessment, pattern recognition. The difference lies in the depth of exposure to inflammatory disease and the synthesis of information across multiple domains. Broadly, three scenarios tend to emerge: * Clinical suspicion + supportive investigations → straightforward diagnosis and initiation of DMARD therapy such as methotrexate. * Strong clinical suspicion but negative tests → cautious treatment trial (NSAIDs, steroid injection) with close follow-up. * Uncertain clinical picture + negative tests → further differentials considered, or a watch-and-wait strategy with review over time. Importantly, there is no “magic blood test.” The real expertise lies in pattern recognition, probabilistic thinking, and appropriately managing uncertainty. For physiotherapists, understanding this process helps refine referrals, manage patient expectations, and appreciate why a definitive answer isn’t always immediate. Rheumatology isn’t about hidden investigations — it’s about high-level clinical reasoning applied consistently and responsibly. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit rheumatologyphysio.substack.com/subscribe

    10 min
  2. We Underestimate This Symptom Of Arthritis (Fatigue)

    FEB 19

    We Underestimate This Symptom Of Arthritis (Fatigue)

    This is a free preview of a paid episode. To hear more, visit rheumatologyphysio.substack.com Welcome Back Rheumatology Fans, Fatigue! The overlooked, underappreciated, oft ignored symptom associated with Arthritis. In this video I go into some detail about why it occurs and why it is so hard to manage, then explain the parameters we can use to actually make improvements! Ideally watch the video but I have put a summary for you below. Fatigue: The Most Under-Appreciated Problem In Inflammatory Rheumatology In this episode, Jack explores what he believes is one of the most under-recognised and poorly managed problems facing people with inflammatory rheumatological conditions: fatigue. While joint pain, stiffness, and function quite rightly receive clinical attention, fatigue is often sidelined—despite being one of the most debilitating symptoms patients report and one of the hardest to treat medically. Jack focuses specifically on auto-inflammatory rheumatological conditions such as rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, lupus, Sjögren’s syndrome, and polymyalgia rheumatica, rather than osteoarthritis or gout. He argues that fatigue in these conditions sits firmly within the therapist’s remit—not just physiotherapists, but all MSK professionals—because medication alone often fails to meaningfully improve it. The episode breaks fatigue down into several key contributing factors. First is a literal sleep deficit. Many inflammatory conditions disrupt sleep, often waking patients in the early hours of the morning due to pain and stiffness. Over years, this creates a chronic lack of restorative sleep, often in people who are still working, raising families, and unable to flex their schedules. Second is immune-driven fatigue. An overactive immune system requires energy and actively promotes tiredness as a protective mechanism—much like the exhaustion felt during flu or infection. In inflammatory disease, this process is switched on constantly, leading to a persistent, unrefreshing fatigue that is largely resistant to disease-modifying drugs. Finally, Jack highlights muscle loss and deconditioning. Chronic inflammation can reduce muscle bulk, activity levels often fall after diagnosis, and even when disease control improves, muscle mass rarely returns fully to baseline. This means everyday tasks require more effort, accelerating fatigue. At around the nine-minute mark, Jack emphasises a key clinical reality: fatigue is multifactorial, chronic, and difficult to “fix.” Patients cannot consciously control their immune system, and pacing strategies—while useful for some—are often impractical, particularly for younger patients with busy lives.

    9 min
  3. Treat To Target For Gout

    FEB 12

    Treat To Target For Gout

    Welcome Back Rheumatology Fans, You have Gout to be joking that I am discussing Gout again! Seriously, fascinating. Article Link: https://jamanetwork.com/journals/jamainternalmedicine/article-abstract/2844321 Watch the video → check out the article! Or below is a summary: People with gout are at significantly higher risk of cardiovascular disease, and this risk should be central to how we assess and manage them in clinical practice. In this episode, the focus shifts beyond gout as an episodic inflammatory arthritis and instead frames it as a condition with important long-term systemic consequences—particularly for cardiovascular health. Evidence consistently shows that individuals diagnosed with gout have an elevated five-year risk of major cardiovascular events such as myocardial infarction and stroke. This increased risk is driven by two main factors. First, gout is a chronic inflammatory condition, and systemic inflammation is a well-established contributor to cardiovascular disease. Second, many of the risk factors associated with gout—such as obesity, hypertension, metabolic syndrome, smoking, and alcohol consumption—overlap with those seen in people at high cardiovascular risk. The combination of these mechanisms means that gout should prompt clinicians to think well beyond joint symptoms alone. A large, robust study involving over 100,000 patients explored whether achieving effective urate control could influence cardiovascular outcomes. Participants with gout were treated with urate-lowering therapy, commonly allopurinol, and outcomes were compared between those who achieved a serum urate level below 6 mg/dL and those who did not. This “treat-to-target” approach resulted in a meaningful reduction in cardiovascular disease risk over five years when compared with usual care. Importantly, the benefits were not limited to cardiovascular outcomes. Patients who achieved the target serum urate level also experienced fewer gout flares, reinforcing that this biochemical target is clinically meaningful and reflective of effective disease control. In addition, subgroup analysis showed that patients who already had a higher baseline cardiovascular risk—such as those with hypertension or a family history of cardiovascular disease—derived the greatest relative benefit. In other words, the people who stand to lose the most from cardiovascular events may also gain the most from optimal gout management. For clinicians working in rheumatology and musculoskeletal care, the implications are clear. A diagnosis of gout should act as a trigger for broader cardiovascular risk assessment. This includes monitoring serum urate levels and aiming for a target below 6 mg/dL, but also addressing modifiable lifestyle factors. Reducing alcohol intake, managing body weight (particularly abdominal adiposity), smoking cessation, and supporting physical activity are all key components of comprehensive care. Pharmacological urate-lowering therapy and lifestyle interventions should be viewed as complementary rather than competing strategies. Physiotherapists and other allied health professionals have an important role to play in recognising cardiovascular risk factors, reinforcing health behaviour change, and ensuring that concerns are escalated appropriately to medical colleagues when needed. Even when cardiovascular management falls outside our direct scope, identifying and flagging risk can make a meaningful difference. Ultimately, treating gout effectively is not just about preventing flares—it is about improving long-term health outcomes. By adopting a treat-to-target approach and integrating cardiovascular risk reduction into routine care, we can significantly improve both joint health and overall wellbeing for people living with gout. Further Resources https://rheumatologyphysio.substack.com/p/investigating-gout This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit rheumatologyphysio.substack.com/subscribe

    6 min
  4. JAN 22

    The EasyJiA Score

    Welcome Back Rheumatology Fans, Every once in a while, I get really excited. This is one of those once in a whiles… This Study (please go and download it etc so it counts for the authors stats and such) aimed to develop and initially validate a scoring system to aid us clinicians decision making for referral to Rheumatology in young people with possible Juvenile Idiopathic Arthritis (JIA). THANK YOU to the authors, I don’t know if I always say that enough. The Study Very briefly because the study design is not the crux of this post. The authors had 342 patients 61 (18%) of which had already been diagnosed with JIA. These were all under 16 and were presenting with joint pains being the primary reason for attendance. Their exclusion criteria included presence of fever (which is a primary symptom of systemic JIA and is a very important separate factor). They collected data from the patients at initial assessment, the patients were diagnosed or not with a specialist with JIA and then the authors did some clever statistical calculations to generate the scoring system. So basically, they gathered information, then the patients were diagnosed and then the authors worked out which were the most useful questions and assigned a scoring system to them based on statistical analysis. The Scoring Criteria The important part for MSK Clinicians, GPs, and anyone else seeing under 16s with joint pains. The authors recommend a score of 3+ providing a sensitivity of 95% bearing in mind this was an initial validation study as they were developing the score. If you use the score you MUST consider your own clinical reasoning and if you are ensure at all, seek advice. This score is still in relatively early in its validation and should not be relied upon too heavily. I have replicated this from the article material as I cannot currently find a downloadable/printable version. Useage Of The Tool Practically this tool is for use when your presenting patients primary complaint is joint pain WITHOUT fever. Of course we would also have considered other relevant pathology and mechanisms of injury. A score of 3+ on the tool supports referral to Rheumatology for further consideration the person has developed Juvenile Idiopathic Arthritis. I cannot stress enough that if you are not sure - get some advice! Further information on Juvenile Idiopathic Arthritis This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit rheumatologyphysio.substack.com/subscribe

    4 min
  5. GLP-1 Agonists In Arthritis And Rheumatology

    JAN 15

    GLP-1 Agonists In Arthritis And Rheumatology

    Welcome Back Rheumatology Fans, 2026… The year of the GLP-1 Agonist? Video Summary In this video, Jack, The Rheumatology Physio, discusses the rapidly growing interest in GLP-1 agonists (such as Ozempic) and their potential role in rheumatology and inflammatory arthritis. I reflect on the increasing public and clinical attention these medications are receiving, particularly as many people report improvements in chronic inflammatory and autoimmune conditions alongside significant weight loss. GLP-1 agonists mimic the body’s natural GLP-1 hormone, helping regulate blood sugar, suppress appetite, and promote weight loss. The key rheumatology question, however, is why some people with conditions such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and osteoarthritis are reporting symptom improvements while taking them. There are two likely mechanisms. First, excess abdominal fat is immunologically active and raises the body’s baseline level of inflammation, which worsens arthritis symptoms and disease activity. By reducing this fat, GLP-1 drugs may lower systemic inflammation, creating an anti-inflammatory shift. Second, emerging evidence suggests these drugs may also directly interact with inflammatory and immune pathways involved in autoimmune disease — meaning their benefits may go beyond weight loss alone. However, at present, GLP-1 agonists are not formally prescribed specifically to treat arthritis. They are currently used for weight management, with any improvement in arthritis considered a secondary benefit. His practical advice is for people with inflammatory arthritis and excess body fat to discuss GLP-1 therapy with their GP or rheumatologist as part of a broader medical plan. He predicts that dedicated rheumatology use of GLP-1 drugs is likely to arrive in the near future as evidence grows. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit rheumatologyphysio.substack.com/subscribe

    8 min
  6. 12/11/2025

    Physiotherapist-Led Weight Management for People with Osteoarthritis

    Welcome Back Rheumatology Fans, I have previously commented that “weight loss for Osteoarthritis is the best bang-for-buck treatment we have currently”: This slide occasionally gets me in hot water with other Physio’s and MSK Professionals but that doesn’t matter to me really, I stand by it and if anything I am becoming more wedded to this stance. Anyway… Ben Steele-Turner is an unstoppable force of Osteoarthritis information and dietary advice. I have shameless updated much of my teaching based on his answers to my questions. NOW HE IS PUBLISHING AS PART OF HIS PhD. His first article is open access HERE. I have written a short summary below but please click on the link and read the article in full. Physiotherapist-Led Weight Management for People with Osteoarthritis This scoping review provides the most comprehensive overview to date of how weight management (WM) is currently understood, implemented, and perceived within physiotherapist-led care for people with osteoarthritis (OA). With 79 records included across 22 countries, the review highlights substantial variability in practice, persistent uncertainty around scope of practice, and a widespread need for improved training and confidence among physiotherapists. Why Weight Management Matters in OAThe evidence linking excess bodyweight to OA (particularly knee OA) is robust. Weight loss of as little as 7% can reduce pain, while more significant reductions can slow structural progression and reduce joint replacement risk. Despite strong guideline recommendations, weight management remains underprovided in OA care. Physiotherapists, who frequently work with people with OA and often have longer consultation times, may be well placed to address this gap. Current Practice: Highly Variable and Often MinimalAcross studies, the proportion of physiotherapists who reported including weight management ranged from very high (over 80% in some survey responses) to extremely low when actual practice was audited. For example, only 12% of individuals with knee OA in one prospective study reported receiving any weight management support during physiotherapy, and note audits showed weight management discussions documented in only about 10% of encounters. People with OA also consistently reported that weight management was either not addressed or addressed only superficially. Scope of PracticePhysiotherapists and people with OA expressed mixed views about whether weight management should fall within physiotherapy’s remit. Many clinicians felt it sat outside traditional physiotherapy roles, often preferring referral to dietitians (admittedly I do this!). However, people with OA who participated in a physiotherapist-led diet-plus-exercise trial reported positive perceptions, especially when physiotherapists had received additional training. This suggests that scope-of-practice concerns may be alleviated when physiotherapists feel more adequately prepared. Confidence and SkillsA recurring theme across the literature is discomfort discussing weight. Physiotherapists commonly feared damaging rapport, felt unsure how to raise weight sensitively, or believed that effective weight management strategies were outside their expertise. Many reported feeling untrained in nutrition or behavioural counselling, and physiotherapy students also identified weight management as a major skill gap. These concerns were echoed by people with OA, who sensed that physiotherapists had limited time and limited practical advice to offer. When weight management was addressed, it was often brief, generic, and lacking actionable support. Education Changes PracticePromisingly, trials of targeted weight management education, such as e-learning modules or structured upskilling programmes, showed clear improvements in physiotherapists’ confidence, knowledge, and attitudes. One physiotherapist-led intervention combining exercise with a structured very low-energy diet yielded clinically significant weight loss and symptom improvements, demonstrating feasibility and safety when clinicians are appropriately trained. Further Resources This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit rheumatologyphysio.substack.com/subscribe

    5 min
  7. Exercise For Rheumatology

    11/27/2025

    Exercise For Rheumatology

    Welcome Back Rheumatology Fans, Exercise (which I like) and Rheumatology (which I also like) make excellent bedfellows but are often misunderstood and misapplied. I listened to a really great podcast on the topic and encourage you to as well. Full Podcast Thank you to The British Society For Rheumatology for publishing. A few takeaways for you below for you to apply in practice, lots more information and specifics for manageing Rheumatological Diseases on my online course, click below to enroll! 1. Exercise in Rheumatology is most effective when it’s personalised, contextualised, and initiated early. A recurring theme throughout the conversation is that “exercise” as a general recommendation is too blunt to be meaningful. Patients often hear the phrase “you should do more exercise” without any guidance about what type, when, how often, or how it fits their symptoms or values. As MSK clinicians, this is where our practice becomes pivotal. Patients take exercise advice most seriously when it comes from a trusted professional — and rheumatology health-care providers consistently rank highly as motivators. The clinical message for physiotherapists is that exercise advice is not a single event but a dialogue. Starting early matters: patients newly diagnosed with inflammatory disease often wait months for physiotherapy input, yet those same months are when they have the most to gain from movement-based reassurance. Even a brief “2-minute conversation” at the end of a medical consult — offering a starting point, normalising safe activity, suggesting step-count increases or simple balance work — can materially shift behaviour. The nuance comes from tailoring. The needs of an 85-year-old trying to maintain independence differ profoundly from a 20-year-old gym-goer. The role of the physio here is functional problem-solving: what matters to the patient? What are they already doing? How can behaviour be shaped using the smallest effective change? And crucially, how can we frame physical activity not as an intimidating prescription but as a spectrum — from daily activities to structured exercise — where all movement confers benefit? 2. All major exercise modalities can help rheumatic disease One of the clearest messages from the podcast is that we do not yet have a single “optimal” exercise type for any rheumatic disease. Aerobic training, strengthening work, flexibility, balance, aquatic exercise, yoga, tai chi — across the major rheumatic conditions, they all show benefit for pain, fatigue, function, sleep, and mood. The data are too heterogeneous to crown a winner, and forcing patients into a pre-chosen modality risks disengagement. For physiotherapists, this reinforces the importance of pragmatic exercise design. Loading principles still matter: tendons respond best to progressive load, bones respond to impact, and cardiovascular systems respond to sustained intensity. But instead of privileging one type of exercise, we should think of the four pillars — aerobic, strength, flexibility, balance/core — as tools we combine based on deficits, goals, and tolerance. The clinical takeaway is that our role is less about choosing the “right” modality and more about identifying the entry point that the patient can and will engage with. Exercise adherence depends more on enjoyment, identity, symptom confidence, and perceived safety than on the physiological superiority of any single training type. As research grows — including forthcoming EULAR guidelines — we may gain sharper distinctions between exercise formats. But right now, for the patient in front of us, the most effective exercise is the one they are willing and able to perform consistently. 3. Sports & Exercise Medicine complements, not replaces, rheumatology The podcast also offers a insight into when referrals to Sport & Exercise Medicine (SEM) can add real value. Three domains stand out: a) MSK pain that doesn’t map cleanly onto inflammatory activity Patients whose rheumatic disease is well-controlled but remain symptomatic often sit in a diagnostic grey zone: biomechanical overload, postural contributors, muscle imbalance, central sensitisation, enthesopathy, coexisting tendon pathology. SEM clinicians can provide extended MSK assessments, diagnostic ultrasound, functional testing, and targeted loading programmes that help physiotherapists refine management. b) Primary tendon pathology Tendons form a significant proportion of SEM workloads. Differentiating tendinopathy from inflammatory enthesopathy is clinically challenging yet critical, particularly around the Achilles, patellar, gluteal, and rotator cuff complexes. SEM assessment can clarify pathology, assist with load-modulation planning, and consider adjunct therapies (e.g., shockwave, injections) when rehabilitation alone is insufficient. This collaboration aligns seamlessly with physio-led progressive loading principles. c) Interventional options For suitable cases, SEM can offer ultrasound-guided interventions including corticosteroid, high-volume injections, nerve blocks, PRP, or shockwave — typically when conservative management has reached its ceiling. For physios working with rheumatology conditions, understanding these options improves referral quality and helps set patient expectations. The broader takeaway is that SEM and rheumatology are highly complementary disciplines that thrive when working in tandem with physiotherapy. The physio is central to longitudinal rehabilitation, behaviour change, and functional recovery; SEM can provide diagnostic clarity and intervention options; rheumatology manages systemic disease. When these three align, patients with complex MSK pain — particularly those with mixed mechanical and inflammatory presentations — tend to do significantly better. Further Resources This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit rheumatologyphysio.substack.com/subscribe

    6 min

About

Content from Rheumatology.Physio projects rheumatologyphysio.substack.com

You Might Also Like